Appointment of Dominique Costantini and Nawal Ouzren the Board of directors
Download the free guide
Boost your gains
Renewal of mandates of directors of Bpifrance, Inserm Transfert and Mr Patrick Langlois
Montpellier, June 8, 2017 17: 45 (CEST) – Sensorion (FR0012596468 ALSEN / Eligible PEA-PME), a biotechnology company specializing in the treatment of diseases of the inner ear, informs that the general Meeting convened on Tuesday, may 30, 2017 approved the renewal of the Board of directors and the appointment of 2 new directors, Mrs. Dominique Costantini, independent director, and Mrs. Nawal Ouzren, Director-general of Sensorion.
Dominique Costantini has more than 20 years of experience in the pharmaceutical industry, where she has accompanied many therapeutic innovations in the field of oncology. She is the executive Director of OSE Immunotherapeutics, a biotechnology company specializing in the development of immunotherapies innovative in the field of oncology, autoimmune diseases and transplantation. Dominique Costantini has also co-founded BioAlliancePharma, specialist of the oncological diseases rare become Onxeo in 2014, where she has carried out the registration of products in Europe and the United States. She is also a director of several biotechnology companies.
The general Assembly has appointed Nawal Ouzren, Director-general, as a new director and renewed the terms of office of directors of Bpifrance Investissement and of Inserm Transfert Initiative, the historical shareholders, as well as Mr. Patrick Langlois, Chairman of the Board. The governance of the company is renewed and supplemented with new skills, with a Board of directors composed of 7 members, including 3 independent directors and more than 40% of women.
Thanks to the input of a professional experienced in the development of products and having a deep knowledge of the industry and the market of the medicine, the Board of directors of Sensorion brings together key competences to carry its portfolio of drug candidates innovative towards new phases of development that create value.
Patrick Langlois, Chairman of the Board of directors of Sensorion, commented : “I am delighted with the diversity and the complementarity of the profiles within the Board of directors of Sensorion, which reflects our strategic aim to become an international player of reference in the treatment of diseases of the inner ear. The experience of Dominique Costantini in the development and commercialization of innovative medicines fits perfectly in the strategy of Nawal Ouzren aimed to intensify the development of Sensorion to the international. ”
●●●
About Sensorion
Sensorion is a biotechnology company specializing in the treatment of the pathologies of the inner ear such as severe dizziness, tinnitus or hearing loss. Two products are in clinical development, the MEANING-111 in phase 2 in the vestibular neuritis acute, and the SENSE-401 has completed a phase 1 study. Based within the Inserm, the Company has strong experience in pharmaceutical R&D and a technological platform to complete to develop medicines for firstin-class easily administrable, in particular oral, for the treatment and prevention of hearing loss and the symptoms of attacks of vertigo and tinnitus, Based in Montpellier, Sensorion has received financial support from Bpifrance, through the InnoBio fund, and
Inserm Transfert Initiative.
Sensorion is listed on Alternext Paris since the month of April 2015. www.sensorion-pharma.com
Download the free guide
Boost your gains
